Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer

被引:21
作者
Sun, Mengmeng [1 ]
Zeng, Han [1 ]
Jin, Kaifeng [1 ]
Liu, Zhaopei [1 ]
Hu, Baoying [2 ]
Liu, Chunnan [1 ]
Yan, Sen [1 ]
Yu, Yanze [1 ]
You, Runze [1 ]
Zhang, Hongyi [1 ]
Chang, Yuan [3 ]
Liu, Li [4 ]
Zhu, Yu [3 ]
Xu, Jiejie [1 ]
Xu, Le [5 ]
Wang, Zewei [4 ]
机构
[1] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Shanghai 200032, Peoples R China
[2] Nantong Univ, Sch Med, Dept Immunol, Nantong, Peoples R China
[3] Fudan Univ Shanghai, Dept Urol, Canc Ctr, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Urol, Shanghai, Peoples R China
[5] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Urol, Sch Med, Shanghai 200025, Peoples R China
基金
中国国家自然科学基金;
关键词
Tumor-associated macrophages; Muscle-invasive bladder cancer; Adjuvant chemotherapy; Immunotherapy; Tumor-immune microenvironment; BLOCKADE;
D O I
10.1007/s00262-021-03098-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Muscle-invasive bladder cancer (MIBC) is an aggressive and heterogeneous malignancy. Tumor-associated macrophages (TAMs) are key infiltrating cell populations in the inflammatory microenvironment of malignant tumors including MIBC. It intrigues us to explore the clinical significance and immunoregulatory role of TAMs infiltration and polarization in MIBC. Methods A total of 141 patients with MIBC from Zhongshan Hospital and 391 patients with MIBC from The Cancer Genome Atlas (TCGA) database were included in this study. Moreover, 195 patients who received anti-PD-L1 therapy from the IMvigor210 trial were enrolled. Patients were categorized into three subtypes considering the infiltration level and polarization status of TAMs, denoted as TAM(low) (Subtype I), TAM(high)&M2/M1(low) (Subtype II), and TAM(high)&M2/M1(high) (Subtype III). Results Subtype III suffered inferior prognosis, and Subtype II could benefit more from adjuvant chemotherapy (ACT). Subtype III was featured with increased pro-tumor cells and immunosuppressive cytokines, while Subtype II possessed more immunogenic cells infiltration with activated and tumoricidal properties. Subtype II and Subtype III presented basal/squamous-like characterization and showed additional prognostic merit beyond molecular classification. Subtype I exhibited elevated level of FGFR3 signature, while Subtype II had EGFR signaling activation and immunotherapeutic indication. Additionally, Subtype II patients were indeed highly sensitive to PD-L1 blockade therapy in IMvigor210 trial. Conclusion The infiltration and polarization status of TAMs shaped distinct immune microenvironment with predictive significance for survival outcome, ACT benefit, and PD-L1 blockade therapy sensitivity in MIBC. Immune classification based on TAMs polarization and infiltration might provide tools to tailor chemotherapy and immunotherapy.
引用
收藏
页码:1497 / 1506
页数:10
相关论文
共 37 条
  • [1] Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
    Chen, Lieping
    Han, Xue
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09) : 3384 - 3391
  • [2] Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
    Choi, Woonyoung
    Porten, Sima
    Kim, Seungchan
    Willis, Daniel
    Plimack, Elizabeth R.
    Hoffman-Censits, Jean
    Roth, Beat
    Cheng, Tiewei
    Mai Tran
    Lee, I-Ling
    Melquist, Jonathan
    Bondaruk, Jolanta
    Majewski, Tadeusz
    Zhang, Shizhen
    Pretzsch, Shanna
    Baggerly, Keith
    Siefker-Radtke, Arlene
    Czerniak, Bogdan
    Dinney, Colin P. N.
    McConkey, David J.
    [J]. CANCER CELL, 2014, 25 (02) : 152 - 165
  • [3] Treatment of muscle-invasive bladder cancer: A systematic review
    Chou, Roger
    Selph, Shelley S.
    Buckley, David I.
    Gustafson, Katie S.
    Griffin, Jessica C.
    Grusing, Sara E.
    Gore, John L.
    [J]. CANCER, 2016, 122 (06) : 842 - 851
  • [4] Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion
    Cioni, Bianca
    Zaalberg, Anniek
    van Beijnum, Judy R.
    Melis, Monique H. M.
    van Burgsteden, Johan
    Muraro, Mauro J.
    Hooijberg, Erik
    Peters, Dennis
    Hofland, Ingrid
    Lubeck, Yoni
    de Jong, Jeroen
    Sanders, Joyce
    Vivie, Judith
    van der Poel, Henk G.
    de Boer, Jan Paul
    Griffioen, Arjan W.
    Zwart, Wilbert
    Bergman, Andries M.
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [5] Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
    Cumberbatch, Marcus George Kwesi
    Jubber, Ibrahim
    Black, Peter C.
    Esperto, Francesco
    Figueroa, Jonine D.
    Kamat, Ashish M.
    Kiemeney, Lambertus
    Lotan, Yair
    Pang, Karl
    Silverman, Debra T.
    Znaor, Ariana
    Catto, James W. F.
    [J]. EUROPEAN UROLOGY, 2018, 74 (06) : 784 - 795
  • [6] Macrophages as regulators of tumour immunity and immunotherapy
    DeNardo, David G.
    Ruffell, Brian
    [J]. NATURE REVIEWS IMMUNOLOGY, 2019, 19 (06) : 369 - 382
  • [7] Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
    Fu, Hangcheng
    Zhu, Yu
    Wang, Yiwei
    Liu, Zheng
    Zhang, Junyu
    Xie, Huyang
    Fu, Qiang
    Dai, Bo
    Ye, Dingwei
    Xu, Jiejie
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (13) : 3069 - 3078
  • [8] CD56 regulates human NK cell cytotoxicity through Pyk2
    Gunesch, Justin T.
    Dixon, Amera L.
    Ebrahim, Tasneem A. M.
    Berrien-Elliott, Melissa M.
    Tatineni, Swetha
    Kumar, Tejas
    Hegewisch-Solloa, Everardo
    Fehniger, Todd A.
    Mace, Emily M.
    [J]. ELIFE, 2020, 9 : 1 - 28
  • [9] Blockade of DC-SIGNthorn Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer
    Hu, Baoying
    Wang, Zewei
    Zeng, Han
    Qi, Yangyang
    Chen, Yifan
    Wang, Tao
    Wang, Jiajun
    Chang, Yuan
    Bai, Qi
    Xia, Yu
    Wang, Yiwei
    Liu, Li
    Zhu, Yu
    Dai, Bo
    Guo, Jianming
    Xu, Le
    Zhang, Weijuan
    Xu, Jiejie
    [J]. CANCER RESEARCH, 2020, 80 (08) : 1707 - 1719
  • [10] Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
    Johnson, Skyler B.
    Yu, James B.
    [J]. CURRENT ONCOLOGY REPORTS, 2018, 20 (09)